methyl 7-keto-5β-cholan-24-oate | 13219-46-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: methyl 7-keto-5β-cholan-24-oate
• 英文别名: methyl (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-7-oxo-1,2,3,4,5,6,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoate
• CAS: 13219-46-0
• 化学式: C₂₅H₄₀O₃
• 分子量: 388.591
• InChiKey: PYHISIRPLRPHGM-XSYVQNARSA-N

物化性质

• 熔点：
  91 °C
• 沸点：
  472.0±18.0 °C(Predicted)
• 密度：
  1.034±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 7-keto-5β-cholan-24-oate 在 sodium tetrahydroborate 作用下， 生成 (5beta,7alpha)-7-羟基胆烷-24-酸
  参考文献：
  名称：

  Preparation and NaBH₄ Reduction of 7-Ketocholanic Acid

  摘要：

  DOI：

  10.1021/ja01651a064
• 作为产物：
  描述：

  3Α-羟基-7-氧代-5Β-胆烷酸 在 乙醚 、 乙醇 、 铂 作用下， 生成 methyl 7-keto-5β-cholan-24-oate
  参考文献：
  名称：

  Serum leptin levels are not influenced by arginine and insulin infusion and by acute changes of GH

  摘要：

  The aim of this study was to evaluate the relationship between GH and leptin in a group of short children and adolescents. Leptin and GH serum levels were measured before and during pharmacological stimulation tests (arginine and insulin) in a group of 45 children (30 male, 15 female), mean age 8.6+/-3.9 yr, affected by idiopathic isolated GH deficiency (GHD), and in a group of 27 children (115 male, 12 female), age 10.9 +/- 3.3 yr, with constitutional growth delay. Results showed that basal and peak leptin levels as well as the AUC were significantly higher in GHD patients compared to controls (p<0.05) and correlated with BMI SDS (p<0.0001) in GHD patients. No change in leptin serum levels was observed during either stimulation test. No correlation was found, however, between basal leptin serum levels and basal, peak and the AUC of GH during the tests. Moreover, no correlation was found between the acute changes of serum GH concentration during both stimulation tests and leptin serum levels. The results suggest that leptin and GH secretion is not correlated and that leptin serum levels mainly reflect the amount of fat tissue, which is higher in GHD patients.

  DOI：

  10.1007/bf03345510

文献信息

• CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES
  申请人：BAR PHARMACEUTICALS S.R.L.

  公开号：US20170190731A1

  公开（公告）日：2017-07-06

  The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.

  本发明涉及具有胆固醇骨架的化合物（I）的公式，所述化合物用于治疗和/或预防FXR和TGR5 / GPBAR1介导的疾病。
• Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
  申请人：BAR PHARMACEUTICALS S.R.L.

  公开号：US10407462B2

  公开（公告）日：2019-09-10

  The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.

  本发明涉及具有式（I）胆烷支架的化合物，所述化合物用于治疗和/或预防 FXR 和 TGR5/GPBAR1 介导的疾病。
• Improved Enantioselectivity in the Epoxidation of Cinnamic Acid Derivatives with Dioxiranes from Keto Bile Acids
  作者：Olga Bortolini、Giancarlo Fantin、Marco Fogagnolo、Roberto Forlani、Silvia Maietti、Paola Pedrini

  DOI：10.1021/jo020146b

  日期：2002.8.1

  The asymmetric epoxidation of substituted cinnamic acids has been obtained in the presence of different keto bile acid derivatives as optically active carbonyl inducers and Oxone as oxygen source. Predominant or almost exclusive formation of both enantiomeric epoxides is obtained (ee up to 95%) depending on the specific substitution at carbons C(7) and C(12) of the bile acid.
• Sawaya, Takuji; Kimura, Michiya, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 4, p. 1207 - 1212
  作者：Sawaya, Takuji、Kimura, Michiya

  DOI：——

  日期：——
• [EN] CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE CHOLANE À UTILISER DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE MALADIES MÉDIÉES PAR FXR ET TGR5/GPBAR1
  申请人：BAR PHARMACEUTICALS S R L

  公开号：WO2015181275A8

  公开（公告）日：2016-02-18